Production (Stage)
Kymera Therapeutics, Inc.
KYMR
$47.62
-$0.04-0.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -25.85% | -40.11% | 86.92% | 71.38% | 70.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.85% | -40.11% | 86.92% | 71.38% | 70.16% |
| Cost of Revenue | 38.85% | 27.06% | 23.52% | 19.49% | 14.74% |
| Gross Profit | -83.04% | -74.84% | -1.09% | 2.25% | 6.14% |
| SG&A Expenses | 15.09% | 15.43% | 17.12% | 22.93% | 24.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.50% | 24.44% | 22.07% | 20.24% | 16.74% |
| Operating Income | -60.72% | -55.08% | -5.64% | -4.90% | -2.04% |
| Income Before Tax | -55.82% | -52.32% | -0.01% | -0.16% | 2.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.82% | -52.32% | -0.01% | -0.16% | 2.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.82% | -52.32% | -0.01% | -0.16% | 2.80% |
| EBIT | -60.72% | -55.08% | -5.64% | -4.90% | -2.04% |
| EBITDA | -60.43% | -54.45% | -4.20% | -3.91% | -1.49% |
| EPS Basic | -23.89% | -17.79% | 19.05% | 12.58% | 12.89% |
| Normalized Basic EPS | -27.43% | -15.03% | 21.47% | 15.10% | 15.31% |
| EPS Diluted | -23.89% | -17.79% | 19.05% | 12.58% | 12.89% |
| Normalized Diluted EPS | -27.43% | -15.03% | 21.47% | 15.10% | 15.31% |
| Average Basic Shares Outstanding | 25.72% | 28.48% | 19.61% | 13.91% | 10.64% |
| Average Diluted Shares Outstanding | 25.72% | 28.48% | 19.61% | 13.91% | 10.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |